New Pharmaceuticals in Diagnosis, Prognosis and Treatment of Myelofibrosis and Myeloproliferative Neoplasms
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (20 February 2025) | Viewed by 311
Special Issue Editors
Interests: essential thrombocythemia; polycythemia vera; myelofibrosis; thrombotic risk; lymphoproliferative disorders; acute leukemias; myelodysplastic syndromes; myeloproliferative disorders
Special Issues, Collections and Topics in MDPI journals
Interests: myeloproliferative disorders; myelodysplastic syndromes; MDS/MPN overlap syndromes; thrombotic risk; lymphoproliferative disorders; acute leukemias; BPDCN; pharmacovigilance; genomics; immunology
Special Issue Information
Dear Colleagues,
The landscape of Philadelphia-negative (Ph) myeloproliferative neoplasms is rapidly changing, and the latest advancements need to be emphasized. The special issue on "New Pharmaceuticals Approach in Diagnosis, Prognosis, and Treatment of Myelofibrosis and Myeloproliferative Neoplasms" highlights the latest advancements in managing these complex hematological disorders, aiming to consolidate cutting-edge research and clinical innovations in this field.
It explores novel diagnostic tools, including molecular and genetic markers, that enhance the accuracy of diagnosis and allow for personalized treatment plans. Advances in prognostic models, which improve the prediction of disease progression and patient outcomes, should also be discussed.
The new therapeutic approaches that are transforming treatment paradigms are central to this issue. The development and application of JAK inhibitors have significantly improved symptom management and disease control in polycythemia vera and myelofibrosis. Emerging pharmaceuticals and combination therapies are also examined for their potential to provide more effective and durable responses, such as new formulations of interferon, BET, MDM2, PI3Kδi, telomerase inhibitors, or the recently developing CALR-targeted immunotherapies.
This compilation of research underscores the importance of a multidisciplinary approach to improving patient care. By integrating novel diagnostic techniques, prognostic tools, and innovative treatments, this special issue aims to provide a comprehensive resource that fosters the translation of research into clinical practice, ultimately leading to better management and outcomes for patients with myelofibrosis and myeloproliferative neoplasms.
This special issue seeks to compile comprehensive insights that will facilitate the translation of research into clinical practice, ultimately improving patient care and outcomes for this setting of patients.
We look forward to your valuable contributions to this important and timely collection.
Dr. Andrea Duminuco
Dr. Calogero Vetro
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- philadelphia-negative Myeloproliferative neoplasms
- JAK2
- CALR
- MPL
- thrombotic risk
- new targeted therapies
- future landscape in MPN
- inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
